1. Discovery and Synthesis of Heterobifunctional Degraders of Rearranged during Transfection (RET) Kinase
- Author
-
Qiao, Jennifer X., Williams, David, Gill, Patrice, Li, Ling, Norris, Derek, Tokarski, John S., Wong, Jessica, Qi, Huilin, Hafeji, Yamnah, Downes, Daniel P., Degnen, Bill, Wang, Ying-Kai, Locke, Gregory, Fang, Hua, Yu, Fei, Xu, Songmei, Naglich, Joseph, Zhang, Jun, Nanjappa, Purushothama, Dai, Chao, Chourb, Lisa, Napoline, Jonathan, Tester, Richland, Jorge, Christine, Li, Yi-Xin, Mathur, Arvind, Barbieri, Christopher, Soars, Matthew G., Venkatanarayan, Avinashnarayan, Lees, Emma, Borzilleri, Robert M., Gavai, Ashvinikumar V., Wichroski, Michael, and Dhar, T. G. Murali
- Abstract
We describe the design, synthesis, and structure–activity relationship (SAR) of heterobifunctional RET ligand-directed degraders (LDDs) derived from three different second-generation RET inhibitors. These LDDs are composed of a target binding motif (TBM) that binds to the RET protein, a linker, and a cereblon binding motif (CBM) as the E3 ligase recognition unit. This led to the identification of a series of pyrazolopyridine-based heterobifunctional LDDs, as exemplified by compound 39. LDD 39demonstrated high in vitro inhibitory and degradation potency against both RET wild-type and the two representative mutants, V804M and G810R. Importantly, in PK/PD studies, 39exhibited a differentiated and favorable in vivo profile compared to the corresponding tyrosine kinase inhibitor (TKI), compound 3. Robust and sustained degradation of total-RET (tRET) protein and inhibition of phospho-RET (pRET) signaling were observed in TPC-1 xenograft tumors driven by RET and the RET/G810R mutant following a single dose of LDD 39at 15 and 75 mg/kg, respectively.
- Published
- 2024
- Full Text
- View/download PDF